Hanneke Jansen
From Wikipedia, the free encyclopedia
Johanna M. Jansen, Ph.D. | |
|---|---|
| Other names | Hanneke |
| Alma mater | Rijksuniversiteit Groningen, Uppsala University |
| Scientific career | |
| Thesis | Three Dimensions in Drug Design: Probing the melatonin receptor |
| Website | https://www.novartis.com/our-science/postdoc-program/leadership/johanna-hanneke-jansen-phd |
Johanna Maria "Hanneke" Jansen is a computational chemist working at Novartis on multiple drug targets. She previously worked at Astra and at Chiron Corporation.[1]
Jansen received her doctoral degree from the University of Groningen (The Netherlands) in 1995, studying computational medicinal chemistry. Her dissertation topic[2] concerned 3D modeling of the melatonin receptor, including work on synthesizing and separating analytes[3][4] to probe its chemistry. She completed a postdoctoral fellowship at Uppsala University in 1997. Her work there related to modeling receptor interactions[5] of drug leads to judge their serotonergic or dopaminergic activities.
Research
Much of Jansen's oeuvre uses in silico methods to study receptor biology, drug design, and drug-protein interactions. An early study (2000) while she was employed at Chiron looked at conformations of the anti-cancer treatment Taxol in nonpolar environments.[6]
In a 2012 commentary for Future Medicinal Chemistry, Jansen led a team of distinguished computational chemists in a call to action, namely that standardized data sets be used across the industry, and that sharing program code between groups at different companies and institutions should be mandated.[7]
A 2017 open-access study in PLoS One related some of Novartis' work - spearheaded by Jansen - to study the oncogenic protein RAS through inhibitors that targeted its inactive conformations.[8]